Dear Sir, We wish to report on severe pancytopenia in a renal transplant recipient with chronic renal failure that occurred after administration of Paludrine® (proguanil hydrochloride; in the following referred to as proguanil) as a prophylactic antimalarial drug and to present hitherto unpublished dosage recommendations for proguanil in patients with renal impairment. A 25-year-old man went to India in July 1993 for a fortnight holiday. He received proguanil as antimalarial prophylaxis at a daily dosage of 200 mg. His original renal diagnosis was endocapiUary proliferative glomerulonephritis; this disease recurred in both renal transplants (1985 and 1992) . One week before departure, the serum creatinine concentration was 398 µmol/l (creatinine clearance 10 ml/min). His additional medication included furosemide, felodipine, alu-col, disodium pamidronate, calcitriol, pred-nisone, and immuran (100 mg daily). Spon- Table 1 . Recommended dosage of proguanil in patients with renal impairment Proguanil dosage Creatinine clearance ml/min/1.73 m2 200 mg once daily 100 mg once daily 50 mg every 2nd day 50 mg once weekly > 60 20-60 10-20 < IO taneous haemorrhages and epistaxis developed 2 weeks after receiving proguanil. Upon admission to our hospital he appeared pale, cushingoid, and dehydrated. Laboratory findings included anaemia (haemoglobin 5.0mmol/l), leucopenia (leucocytes 2.7/nl) with granulopenia (1.28/nl), and thrombope-nia (17/nl). The serum creatinine level had increased to 641 µmol/l. It was concluded that the pancytopenia was caused by a proguanil intoxication. Proguanil and immuran were withheld; additional treatment included thrombocyte concentrates, rehydration, and folic acid. Renal replacement therapy had to be restarted. Both thrombopenia and leucopenia disappeared after 10 days. He eventually made a full recovery though maintenance therapy had to be continued. Proguanil is generally considered a safe and effective antimalarial drug with few reported side effects [1] . To our knowledge, only two reports of three similar cases with renal impairment and pancytopenia caused by proguanil have been published [2, 3] . Proguanil and its active metabolite cycloguanil, a potent inhibitor of dihydrofolate reduc-tase, are predominantly excreted by the kidneys [4, 5] . Therefore, accumulation of the drug is to be anticipated in patients with renal failure, and the dosage has to be adapted in patients with renal impairment. In table 1 a hitherto unpublished dose regimen is presented for proguanil in patients with renal impairment. This regimen is based on a human dose finding study, initiated by Zeneca Pharma. This study indicated that the maximum plasma concentration, the area under the curve, and the half-lives of proguanil and its metabolites all increased as the renal function decreased. The presented dose regimen should keep the steady state blood cycloguanil concentrations between 15 and 270 µg/l. This is higher than the minimum effective concentration and below toxic concentrations. Haemodialysis and in-traperitoneal dialysis had little effect on the pharmacokinetics of proguanil and its metabolites. Today's rapidly expanding international travelling with inherent malaria prophylaxis will not exclude renal patients. Nephrolo-gists should be aware of the potential risks and adapt the dosage of proguanil accordingly in patients with renal impairment.
